Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –
– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –
– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden.
